Curasight has resolved upon a directed share and warrant issue, and has also issued convertible debt, a strategy that should fund operations through 2024 and, via the warrants, potentially up to uTREAT first patient in (FPI), in mid-2025. The plan should help strengthen the balance sheet, in our view, and strikes a balance between dilutive and non-dilutive funding that should help repair damage to the shares from the previously planned rights issue.

Link to the analysis